NCT02456935View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Erosive Esophagitis
Interventions
DRUG

CJ-12420 100 mg QD

CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.

DRUG

Esomeprazole 40 mg QD

Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY